ANCA-associated vasculitis
Management of ANCA-associated vasculitis: Current trends and future prospects
... Maintenance of remission in ANCA-associated vasculitis requires long-term immunosuppression in most patients. Therapy usually consists of long-term low-dose glucocor- ticoids together with a second ...
12
Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study
... (ANCA)-associated vasculitis (AAV) with renal ...of ANCA-associated vasculitis were included in this ...factors associated with infection were age at the time of diagnosis ...
7
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.
... 11. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. The New England journal of medicine. 2014 ...
15
Epitope specificity determines pathogenicity and detectability in ANCA associated vasculitis
... necrotizing vasculitis is caused by immune-mediated inflammation of the vessel wall and is diagnosed in some cases by the presence of myeloperoxidase-specific antibodies ...in ANCA epitope specificity ...
12
Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis
... In ANCA-associated vasculitis the acute phase of the disease is often preceded by prodromal ...with ANCA-associated vasculitis and renal involvement from a retrospective ...
7
Long term outcome of patients with ANCA associated vasculitis treated with plasma exchange: a retrospective, single centre study
... Renal Vasculitis (MEPEX) randomised trial, patients with severe renal vasculitis who received PLEX as adjunctive therapy had higher probability of dialysis independence at 1 year than patients treated with ...
6
Fatal pulmonary complication during induction therapy in a patient with ANCA-associated vasculitis
... ANCA-associated vasculitis (AAV) is an inflammatory systemic disorder affecting small to medium sized vessels and likely lead- ing to any organ ...in vasculitis patients even an intensive ...
5
The frequency of ANCA associated vasculitis in a national database of hospitalized patients in China
... 21. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DRW, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hru š ková Z, ...
10
The characterisation and determinants of quality of life in ANCA associated vasculitis
... The judicious use of immunosuppressants has transformed traditional outcomes for patients with ANCA-associated vasculitis (AAV). Mortality rates, previously exceeding 80% at 1 year [1], have been ...
6
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist
... of vasculitis) trial, patients with a newly diagnosed severe AAV and a serum creatinine of < 500 μmol/L in whom remission had been achieved within 3–6 months, were randomly assigned to continue poCYC or switch ...
15
Platelets are activated in ANCA associated vasculitis via thrombin PARs pathway and can activate the alternative complement pathway
... We collected plasma samples from 14 active AAV patients before the initiation of immunosuppressive therapy for platelets stimulation. Among these 14 pa- tients, 7 were male and 7 were female, with an average age of 52.0 ...
10
Alpha-1 Antitrypsin Deficiency Presenting with MPO-ANCA Associated Vasculitis and Aortic Dissection
... Complex elective endovascular treatment of aortic pathology in patients with suspected connective tissue disorders is controversial because of high reintervention and complication rates [6]. Together with the patient, we ...
5
MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination
... Blood tests showed raised levels of erythrocyte sedi- mentation rate (ESR) and C-reactive protein (CRP), a mild normocytic anaemia, leukocytosis and normal renal function (creatinine 87 μmol/l) (Table 1). At admission ...
5
Plasma complement factor H is associated with disease activity of patients with ANCA associated vasculitis
... PR3-ANCA-positive vasculitis were excluded because increasing evidence suggests that MPO-AAV and PR3-AAV are two distinct entities [14, ...perinuclear ANCA (P-ANCA) and MPO-ANCA at ...
9
Is serum HMGB1 a biomarker in ANCA associated vasculitis?
... Results: HMGB1 levels were similar between AAV patients at presentation (n = 52) and HC (n = 35) (2.64 ± 1.80 ng/ml vs. 2.39 ± 1.09 ng/ml; P = 0.422) and no difference regarding HMGB1 levels could be found among AAV ...
9
ANCA-Associated Vasculitis: Advancement in Pathogenesis, Clinical Features and Management
... The treatment of EPGA includes glucocorticoids, azathioprine, and cyclophosphamide. The management should include continuous clinical monitoring. In EGPA patients with moderate to severe allergic asthma, rituximab and ...
7
ANCA-associated vasculitis in childhood: recent advances
... endothelial cell and tissue damage, leading to inflamma- tion of the vessel wall and- in GPA- granuloma forma- tion [24]. Strong in vivo and in vitro evidence supports the pathogenic role of ANCA. ANCAs are ...
9
In vivoapproaches to investigate ANCA associated vasculitis: lessons and limitations
... MPO-ANCA vasculitis rodent models have proven to be very valuable for in vivo studies of eff ector mechanisms involved in the acute vascular infl ammatory phase and for the evaluation of experimental ...
10
Progress in treatment of ANCA associated vasculitis
... AAV includes (Wegener’s) granulomatosis with poly angi- itis (GPA), microscopic polyangiitis (MPA) and Churg- Strauss syndrome (CSS). Th ese conditions are usually associated with the presence of circulating ...
12
Reanalysis of the Rituximab in ANCA Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment
... and ANCA in disease pathophysiology is well known. ANCA targeting primary granule antigens expressed on the neutrophils are known to elicit neutrophil activation and degranula- tion and subsequently mediate ...
11